添加微信 添加微信
添加微信
首页: 全球医药政策

德国-Profil

时间:2021-10-21 15:09:25 来源:康安医药咨询 作者:康安医药咨询

Founded in 1999, Profil has grown to become a unique full-service CRO with an excellent record for professional conduct and scientific expertise in clinical research on diabetes and other metabolic diseases. The Profil Institut für Stoffwechselforschung GmbH (in English Profil Institute for Metabolic Research), began life as a spin-off of an academic study group at the Department of Metabolic Diseases and Nutrition at the University of Düsseldorf. Our founders wished to create a dedicated CRO that would address the challenges of diabetes and obesity research and treatment. The company’s achievements are testament to that vision. Over the years, we have implemented numerous sophisticated methods for pharmacodynamic characterization of the effects of compounds in early phase trials, and we have been involved in the development of all the currently available major anti-diabetic compounds. Our key competence is the performance of glucose clamp studies, often combined with isotope dilution techniques and muscle or fat biopsies.diabetic compounds. Our key competence is the performance of glucose clamp studies, often combined with isotope dilution techniques and muscle or fat biopsies.

Phone: 49, 2131, 4018-0 Fax: 49, 2131, 4018-500 E-mail: marketing@profil.com
Web: https://www.profil.com
Add:Hellersbergstraße 9,41460 Neuss,Deutschland

想要下载更多资料,请您添加微信了解详情!

微信号:csco2022

公众号:康安医药咨询

当前栏目

频道栏目

最新文章

热门文章